[go: up one dir, main page]

WO2001096391A3 - 55p4h4: gene expressed in various cancers - Google Patents

55p4h4: gene expressed in various cancers Download PDF

Info

Publication number
WO2001096391A3
WO2001096391A3 PCT/US2001/019246 US0119246W WO0196391A3 WO 2001096391 A3 WO2001096391 A3 WO 2001096391A3 US 0119246 W US0119246 W US 0119246W WO 0196391 A3 WO0196391 A3 WO 0196391A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
various cancers
gene expressed
fragment
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019246
Other languages
French (fr)
Other versions
WO2001096391A2 (en
Inventor
Mary Faris
Rene S Hubert
Daniel E H Afar
Elana Levin
Steven Chappell Mitchell
Arthur B Raitano
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to EP01946410A priority Critical patent/EP1294875A2/en
Priority to AU2001268466A priority patent/AU2001268466A1/en
Publication of WO2001096391A2 publication Critical patent/WO2001096391A2/en
Publication of WO2001096391A3 publication Critical patent/WO2001096391A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A novel gene (designated 55P4H4) and its encoded protein are described. While 55P4H4 exhibits tissue-restricted expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, lung, testis, bone, cervical, brain, and ovarian cancers. Consequently, 55P4H4 provides a diagnostic and/or therapeutic target for cancers, and the 55P4H4 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
PCT/US2001/019246 2000-06-13 2001-06-13 55p4h4: gene expressed in various cancers Ceased WO2001096391A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01946410A EP1294875A2 (en) 2000-06-13 2001-06-13 55p4h4: gene expressed in various cancers
AU2001268466A AU2001268466A1 (en) 2000-06-13 2001-06-13 55p4h4: gene expressed in various cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21145400P 2000-06-13 2000-06-13
US60/211,454 2000-06-13

Publications (2)

Publication Number Publication Date
WO2001096391A2 WO2001096391A2 (en) 2001-12-20
WO2001096391A3 true WO2001096391A3 (en) 2002-12-05

Family

ID=22786990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019246 Ceased WO2001096391A2 (en) 2000-06-13 2001-06-13 55p4h4: gene expressed in various cancers

Country Status (3)

Country Link
EP (1) EP1294875A2 (en)
AU (1) AU2001268466A1 (en)
WO (1) WO2001096391A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723052B2 (en) 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (en) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes
WO1999051727A2 (en) * 1998-04-03 1999-10-14 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal ovary tissue
WO2000044902A2 (en) * 1999-01-29 2000-08-03 G.D. Searle & Co. Biomarkers and assays for carcinogenesis induced by phenobarbitol
WO2001051513A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
WO2001057207A2 (en) * 2000-02-04 2001-08-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001074901A2 (en) * 2000-03-31 2001-10-11 Scios Inc. Polynucleotides and polypeptides, their use in diagnosis and treatment of cardiac, renal or inflammary disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (en) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes
WO1999051727A2 (en) * 1998-04-03 1999-10-14 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid sequences of normal ovary tissue
WO2000044902A2 (en) * 1999-01-29 2000-08-03 G.D. Searle & Co. Biomarkers and assays for carcinogenesis induced by phenobarbitol
WO2001051513A2 (en) * 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
WO2001057207A2 (en) * 2000-02-04 2001-08-09 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001074901A2 (en) * 2000-03-31 2001-10-11 Scios Inc. Polynucleotides and polypeptides, their use in diagnosis and treatment of cardiac, renal or inflammary disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SEQUENCE LIBRARY 2 May 2000 (2000-05-02), TSAI, S.F.: "Genome Sequencing of the Chromosome 4q Region Implicated in Human Hepatocellular Carcinoma Pathogenesis 1 - Homo sapiens genomic DNA, chromosome 4q22-q24, clone:2190A3", XP002196337 *
DATABASE EMBL SEQUENCE LIBRARY 22 July 1997 (1997-07-22), NCI-CGAP: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index http://www.ncbi.nlm.nih.gov/ncicgap - nj15d07.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:986413 3', mRNA", XP002196336 *
DATABASE EMBL SEQUENCE LIBRARY 9 February 2001 (2001-02-09), ADACHI, J., ET AL.: "functional annotation of a full-length mouse cDNA collection - Mus musculus adult male testis cDNA, RIKEN full-length enriched library clone:1700108M02:homolog to CDNA FLJ20500 FIS, CLONE KAT09159, full insert", XP002196338 *
DATABASE TREMBL DATABASE 1 June 2001 (2001-06-01), KAWAI,J., ET AL.: "functional annotation of a full-length mouse cDNA collection", XP002196339 *
TJOA B ET AL: "PRESENTATION OF PROSTATE TUMOR ANTIGENS BY DENDRITIC CELLS STIMULATES T-CELL PROLIFERATION AND CYTOTOXICITY", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 28, no. 1, 1996, pages 65 - 69, XP000605663, ISSN: 0270-4137 *
XUE B-H ET AL: "INDUCTION OF HUMAN CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR PROSTATE- SPECIFIC ANTIGEN", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 30, no. 2, 1997, pages 73 - 78, XP000878867, ISSN: 0270-4137 *

Also Published As

Publication number Publication date
WO2001096391A2 (en) 2001-12-20
AU2001268466A1 (en) 2001-12-24
EP1294875A2 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
WO2005062972A3 (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2002016593A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2001062778A3 (en) Tumour-specific animal proteins
WO2001083739A3 (en) Human pellino polypeptides
WO2001077289A3 (en) Polynucleotides encoding novel secreted proteins
WO2001077288A3 (en) Polynucleotides encoding novel secreted proteins
WO2001096391A3 (en) 55p4h4: gene expressed in various cancers
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
WO2002028889A3 (en) Haemophilus influenzae antigens and corresponding dna fragments
EP0839908A3 (en) A novel human ETS family member, ELF3
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2001062925A3 (en) 103p2d6: tissue specific protein highly expressed in various cancers
WO2001079557A3 (en) Gtp-binding protein useful in treatment and detection of cancer
WO2004072263A3 (en) Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2002018578A3 (en) Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
WO2001059115A3 (en) 83p5g4: a tissue specific protein highly expressed in prostate cancer
WO2001090157A3 (en) 98p7c3: homeodomain protein highly expressed in various cancers
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer
AU2001289930A1 (en) Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
WO2001031343A3 (en) Diagnosis and therapy of cancer using sgp28-related molecules
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
WO2001092524A3 (en) Myosin-like gene expressed in human heart and muscle
WO2002014501A3 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001946410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946410

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001946410

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP